ClinicalTrials.gg
Sign In
Drug

ARQ531 clinical trials

Also written Nemtabrutinib, MK-1026 and ARQ 531.

studies test it
24
open now
12
in phase 3
3
first study started
2017

How each study uses ARQ531 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ARQ531 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Bruton's Tyrosine Kinase Inhibitor ARQ 531
5
BTK Inhibitor ARQ 531
5

Development codes

MK-1026
22
ARQ 531
20

Other names

Nemtabrutinib
24

Studies by the year they started

24 studies that test it; most in 2023 (10)

Studies that test ARQ531, by start year
YearStudies
20171
20211
20221
202310
20241
20252
20268

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
10
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Leukemia, Lymphocytic, Chronic, B-Cell
7
Hematologic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
1

Who runs them

Industry 16 · Other 8

Merck Sharp & Dohme LLC (15) · City of Hope Medical Center (2) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Medical College of Wisconsin (1) · Fred Hutchinson Cancer Center (1) · Jennifer Woyach (1) · Roswell Park Cancer Institute (1)

Often tested with

Tested in the same studies.

Digoxin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test ARQ531, phase 3 first.

Studies

Open first, then newest update. How each study uses ARQ531 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 24

See all 24 studies that test ARQ531 →

Given beside what is tested · 1 — ARQ531 is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting1

Codes

What other systems call ARQ531 · ClinicalTrials.gg INT001794

  • MeSH (NLM) C000721068ARQ531One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.